Navigation Links
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
Date:2/3/2009

al results, will better position us to secure an optimal partnership arrangement for R788," said James M. Gower, Chairman and Chief Executive Officer. As for the program cuts, Mr. Gower said, "Rigel has been blessed with a prolific research organization whose members are dedicated and talented professionals. However, we have come to the point in time, where we can no longer continue to support all of the programs we have generated. The company needs to focus on moving our most advanced projects forward, including, in the case of R788, potentially into Phase 3 clinical trials."

Update on the Phase 2b, TASKi2 and TASKi3, Clinical Trials:

Enrollment for the TASKi2 clinical trial of R788 in patients with rheumatoid arthritis (RA) who have previously failed to respond to methotrexate treatment was completed in December 2008, with 457 patients randomized. The smaller TASKi3 clinical trial of R788 is on track to complete enrollment in April 2009 with an expected enrollment of 195 patients with RA who have previously failed to respond to at least one marketed biologic treatment. Both clinical trials are multi-center, randomized, double-blind, and placebo controlled.

The primary objectives for TASKi2 and TASKi3 are to measure the efficacy of R788 at 6 months and 3 months, respectively, as determined by ACR20 scores (American College of Rheumatology responder rates showing a minimum of 20% improvement in RA symptoms and pain). Secondary objectives will include comparing higher ACR response rates (ACR 50 and ACR 70), as well as DAS28 rates (Disease Activity Score including a 28-joint inspection), in addition to various safety measures. TASKi3 will also include measurement of changes in bone morphology using magnetic resonance imaging (MRI) scans as a secondary measure. In addition, Rigel will continue to develop R788 in various lymphomas and is currently conducting a clinical trial in T-cell lymphoma.'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
2. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
3. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
6. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
8. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the availability of the ResMed Data Exchange program, ... for home medical equipment (HME) and other health ... offers timely, secure access to critical patient information. ... from ResMed,s AirView™ and U-Sleep™ patient management platforms ...
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
(Date:10/20/2014)... Oct. 20, 2014   Taiho Oncology, Inc. ... ( Japan ), announced that the ... Track designation for TAS-102 (nonproprietary names: trifluridine and ... investigation for the treatment of refractory metastatic colorectal ... a rolling NDA submission to the FDA. According ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Oct. 1 FASgen,s fatty acid synthase,inhibitor (FASi) ... solid tumor xenograft cell line tested, in both ... (H460; A549; H1975; LX7); two,ovarian; breast; and, colon. ... compounds have been shown in extensive preclinical studies ...
... Show Patients with Moderate to Severe Psoriasis Who Responded to, Anti-IL-12/23 ABT-874 ... ... 24 Weeks, BUENOS AIRES, Argentina, Oct. 1 ... Abbott,s,(NYSE: ABT ) investigational anti-IL-12/23 antibody ABT-874 showed that a,majority of ...
Cached Medicine Technology:FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 3Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 4
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... 2014 Punzoné , the first line ... has a lot to celebrate this month. October marks Italian ... achievements and contributions of Americans of Italian heritage and Italians ... today it shares its favorite Italian cocktails and encourages everyone ... - even if it is only in a glass. ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 The ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the ... excellent platforms for those who want to buy ... same time. , The IT manager of Top10BestSEOHosting.com ... the most recommended suppliers for everyone. A lot ...
(Date:10/19/2014)... been working in the garment industry for decades, LunaDress’ dress ... James, one of the company’s top designers, many ladies like ... that add beauty to them. Chiffon floor length outfits are ... new selection of 2014 long prom dresses. , As ... available in over 20 popular designs. The company intends to ...
(Date:10/19/2014)... Visual Impact Frequency Training - a ... to the public generating a frenzied buzz of ... community. The commotion surrounding the program's launch has ... an investigative review. , "Many gym-goers are familiar ... known as a training 'plateau' where they are ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... Giving low-dose aspirin to patients after they,ve received stronger blood ... odds of redeveloping the clots, a new study finds. ... include both the leg clots known as deep-vein thromboses, or ... pulse, shortness of breath, chest pain and even death. ...
... interim analysis of a phase Ib/II clinical trial indicates that ... highly active and well tolerated in patients who have relapsed ... is the first drug designed to target Bruton,s tyrosine kinase, ... the most common form of leukemia, with about 15,000 new ...
... treating chronic lymphocytic leukemia has produced durable remissions in ... or resistant disease, investigators report at the 53rd Annual ... one of a new class of experimental drugs called ... this clinical trial for its effectiveness and particularly for ...
... significantly in adults with the bleeding disorder hemophilia B ... researchers at St. Jude Children,s Research Hospital in Memphis ... conducted at the University College London (UCL) in the ... the first proof that gene therapy can reduce disabling, ...
... University Hospital and Kimmel Cancer Center at Jefferson ... gene (RB) in triple negative breast cancer patients is associated ... identify the subset of these patients who may respond positively ... in care of triple negative breast cancer, and as a ...
... By Denise Mann HealthDay Reporter , FRIDAY, ... undergo a procedure to treat an irregular heartbeat known as ... life after the treatment than their thinner counterparts. The ... HeartRhythm . Atrial fibrilation (AF) greatly increases a person,s ...
Cached Medicine News:Health News:Low-Dose Aspirin After Lung Clot Could Prevent Recurrence 2Health News:Low-Dose Aspirin After Lung Clot Could Prevent Recurrence 3Health News:Novel experimental agent is highly active in CLL patients, interim study shows 2Health News:B cell receptor inhibitor causes chronic lymphocytic leukemia remission 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 3Health News:SABCS: Loss of RB in triple negative breast cancer associated with favorable clinical outcome 2Health News:Obese Patients May Benefit the Most From Surgery for Irregular Heartbeat 2
Inquire...
... Calf Implants are available ... sizes. They are available non-sterile ... and sold individually. Depending on ... may use one or two ...
... the IQmark family elevates your ECG and Spirometry ... cost-savings and efficient patient care. The IQmark Diagnostic ... office, clinics and medical centers as well as ... in conjunction with the IQmark Digital ECG PDA ...
... data-gathering extension of the IQmark Diagnostic Workstation, ... Windows-based PC to deliver unmatched speed, accuracy ... Now you can download and seamlessly integrate ... simple click of a mouse. The point-and-click ...
Medicine Products: